Arrowgrass Capital Partners (US)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-60,000	Closed	-$4.58M	–	148
2019 Q3	$4.58M	Sell	60,000 -10,000	-14%	-$831K	0.34%	82
2019 Q2	$6.14M	Hold	70,000	–	–	0.15%	174
2019 Q1	$6.34M	Hold	70,000	–	–	0.19%	158
2018 Q4	$5.02M	Buy	+70,000	New	+$5.64M	0.19%	140
2017 Q2	–	Sell	-211	Closed	-$1.46M	–	629
2017 Q1	$1.46M	Hold	211	–	–	0.02%	453
2016 Q4	$1.25M	Sell	211 -250	-54%	-$15.4K	0.01%	410
2016 Q3	$3.06M	Buy	+461	New	+$28.5K	0.04%	261

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s XBI Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2019, closing a stake of 26,974 shares — an estimated $2.06M sold.

Arrowgrass Capital Partners (US) first reported a position in XBI in Q1 2017 and held it in 3 quarters. The position peaked at $2.45M in Q4 2018. 474 funds tracked by Wall St. Rank hold XBI as of Q4 2019.

Arrowgrass Capital Partners (US) reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2019 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 26,974 State Street SPDR S&P Biotech ETF shares in Q4 2019, an estimated $2.06M.
Arrowgrass Capital Partners (US) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 3 quarters.
Arrowgrass Capital Partners (US)'s State Street SPDR S&P Biotech ETF position peaked at $2.45M in Q4 2018.
474 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.